Unable to load price data. Sorry.

¯\_(ツ)_/¯

King Pharmaceuticals, Inc. (NYSE:KG)

CAPS Rating: No stars

The Company is a vertically integrated pharmaceutical company that develops, manufactures, markets and sells branded prescription pharmaceutical products.

Unable to load market data for this Ticker. Sorry.

¯\_(ツ)_/¯

Caps

How do you think NYSE:KG will perform against the market?

Add Stock to CAPS Watchlist

All Players

344 Outperform
38 Underperform
 

All-Star Players

49 Outperform
10 Underperform
 

Wall Street

5 Outperform
2 Underperform
 

Top NYSE:KG Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Survivn2 (45.80)
Submitted October 16, 2008

Pharma in rough times, MFI. Smaller cap than I wanted, but we'll give it a try.

aladha (62.65)
Submitted April 15, 2008

Maybe good long term once they get some direction but the market shares for their "blockbuster" products in terms of actual Rx's dispensed plus huge debt load relative to current position points to this one being flat at best until they manage to… More

NYSE:KG VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about KG.

Recs

0
Member Avatar btthus (< 20) Submitted: 10/12/2010 11:10:01 AM : Outperform Start Price: $14.16 NYSE:KG Score: -157.06

Price is now 14.15....
Pfizer will acquire King Pharma for $14.25 per share.

Recs

0
Member Avatar coryjobe (94.72) Submitted: 7/24/2010 3:58:39 PM : Outperform Start Price: $8.51 NYSE:KG Score: -112.92

Recently had a slight setback with their drug Acurox, FDA rejected it but there is still a chance that it will get passed if the regulator says its ok. Right now they plan on submitting a new application in early 2011 with a new version of the drug that will have much better odds of getting approved. This company might not have much growth short term, but in the long term should be very profitable. They have a large number of drugs which should boost numbers in the next couple of years. Also a court ruling is causing one of the generic competitors Skelaxin off the market for now.

Recs

0
Member Avatar fooljh123457 (< 20) Submitted: 8/17/2009 5:37:15 PM : Outperform Start Price: $10.43 NYSE:KG Score: -169.41

new technology they have fixed it to prevent abuse of over doing for affect. docs will be more likely to prefer this med over others that can be abused for recreation purposes. docs will flock to this med!

Leaderboard

Find the members with the highest scoring picks in KG.

Score Leader

nyctola

nyctola (53.86) Score: +195.68

The Score Leader is the player with the highest score across all their picks in KG.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
nyctola 53.86 1/8/2009 Underperform 3M $10.03 +41.97% +237.66% +195.68 0 Comment
EliteMerchant 97.97 10/10/2008 Underperform 5Y $7.51 +89.61% +254.77% +165.16 0 Comment
tatsumaki4ryu < 20 9/8/2006 Underperform 3Y $16.26 -12.42% +145.86% +158.29 0 Comment
PurePwnage 99.34 11/27/2009 Underperform 5Y $11.81 +20.58% +176.76% +156.19 0 Comment
NAVSKI 38.35 10/4/2006 Underperform 5Y $17.10 -16.73% +136.83% +153.56 0 Comment
DiamondDawg 97.18 11/25/2009 Underperform 5Y $12.10 +17.69% +169.87% +152.18 0 Comment
TrackDuality < 20 11/9/2009 Underperform 5Y $11.26 +26.47% +177.92% +151.45 0 Comment
39272x4 22.17 11/9/2009 Underperform 5Y $11.26 +26.47% +177.92% +151.45 0 Comment
MSFOBV1YH 99.19 11/10/2009 Underperform 5Y $11.41 +24.80% +174.46% +149.66 0 Comment
JulesWinnfield 99.40 12/14/2009 Underperform 5Y $11.66 +22.13% +168.18% +146.05 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackCarisandCo 87.10 6/9/2010 Outperform NS $7.71 +84.70% +179.76% -95.06 0 Comment
TrackZacks < 20 5/5/2010 Underperform 3M $9.64 -4.77% -3.28% +1.49 8/9/2010 @ $9.18 1 Comment
TrackBMOCapital < 20 4/23/2010 Underperform NS $11.12 +28.06% +148.07% +120.01 0 Comment
TrackGoldmanSach 76.74 4/22/2010 Underperform 5Y $11.38 -23.11% -7.76% +15.35 7/26/2010 @ $8.75 1 Comment
TrackLazardCapit < 20 10/8/2009 Outperform NS $10.36 +37.45% +181.57% -144.12 0 Comment
TrackZacks < 20 8/21/2009 Underperform 3M $10.50 +17.05% +11.30% -5.75 3/9/2010 @ $12.29 1 Comment
TrackZacks < 20 7/8/2009 Outperform 3M $9.27 +13.27% +16.86% -3.60 8/21/2009 @ $10.50 1 Comment
TrackUBS 89.71 4/20/2009 Outperform NS $8.84 +60.18% +38.22% +21.96 10/13/2010 @ $14.16 0 Comment
TrackWellsFargo 87.95 3/16/2009 Outperform NS $7.45 +91.14% +296.73% -205.59 0 Comment
TrackCowenandCo 71.39 11/14/2008 Outperform NS $9.64 +47.72% +244.21% -196.49 0 Comment
TrackJGreenblatt 43.47 4/11/2008 Outperform 1Y $8.88 -0.45% -36.51% +36.06 4/20/2009 @ $8.84 2 Comments
TrackSoros 84.64 9/30/2007 Outperform NS $11.72 +21.50% +106.01% -84.51 1 Comment
TrackCitigroup 85.93 7/17/2007 Underperform NS $19.00 -43.16% -1.39% +41.77 10/19/2007 @ $10.80 0 Comment
TrackZacks < 20 6/21/2007 Underperform 3M $20.51 -43.78% -14.34% +29.45 8/29/2008 @ $11.53 1 Comment
TrackJGreenblatt 43.47 1/1/2007 Outperform 1Y $15.92 -35.62% +3.69% -39.31 1/2/2008 @ $10.25 1 Comment
TrackBroadpointAmTech < 20 12/20/2006 Underperform NS $16.17 -15.03% +1.20% +16.23 8/10/2007 @ $13.74 0 Comment
TrackJimCramer 86.32 6/9/2006 Underperform 3W $16.50 -13.70% +155.38% +169.08 0 Comment
TrackJGreenblatt 43.47 4/13/2006 Outperform 1Y $17.65 -9.07% +10.05% -19.11 1/1/2007 @ $16.05 0 Comment